Results 181 to 190 of about 271,655 (296)

Correction to "Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank". [PDF]

Case Rep Oncol Med
europepmc   +1 more source

Response to Comment on: "Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?" [PDF]

Haematologica
Dann EJ.
europepmc   +1 more source

Elevated lymphoma risk in patients with chronic pruritus and chronic prurigo

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Chronic pruritus (CP) and chronic prurigo (CPG, including prurigo nodularis) are prevalent, debilitating diseases with diverse comorbidities, including malignancies. This retrospective cohort study evaluated the prevalence and risk of lymphoma in CP and CPG patients, including key risk factors, and sex‐ and ancestry ...
Svenja Royeck, Henning Olbrich, Steffen Koschmieder, Claudia Zeidler, Felix Witte, Konstantin Agelopoulos, Henning Wiegmann, Michael Storck, Johannes Benedict Oehm, Ralf J. Ludwig, Sonja Ständer   +10 more
wiley   +1 more source

CD161 and LLT1 expression in immune cell populations of Hodgkin lymphoma tumor microenvironment. [PDF]

Front Med (Lausanne)
Rjoop A, Al-Samama'h R, Al-Eitan L.
europepmc   +1 more source

The Lymphoma Information Network

The Lymphoma Information Network website strives to "put a bit of humanity and understanding to this disease, to gather lymphoma information and resources in one place, and to present information in an easy to understand and logical format." ...

core  

Current state of medical care for patients with mycosis fungoides and Sézary syndrome at a German university hospital – a cross‐sectional study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Studies on the state of medical care for patients with cutaneous T‐cell lymphoma (CTCL) are limited. To date, only secondary data analyses are available for Germany. Patients and Methods Cross‐sectional study conducted over a one‐year recruitment period (01 March 2024 to 28 February 2025) in the dermatological department of a German ...
Inga Hansen‐Abeck, Larissa Kölln, Finn Abeck, Glenn Geidel, Stefan W. Schneider, Nina Booken   +5 more
wiley   +1 more source

Validation of the newly introduced Deauville score 5a for patients treated for advanced-stage classic Hodgkin lymphoma. [PDF]

Blood Adv
Leiders S, Ufton D, Kaul H, Weindler J, Rosenbrock J, Fuchs M, Dietlein M, Novak U, Fehr M, Greil R, Hertzberg M, Zijlstra JM, Fosså A, Kamper P, Molin D, Borchmann P, Kobe C, Ferdinandus J.   +17 more
europepmc   +1 more source

[Malignant lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma)].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2012
openaire   +2 more sources

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Mechanisms of resistance to macrophage checkpoint inhibitors in B-cell non-Hodgkin lymphoma. [PDF]

Br J Haematol
Hunzeker Z, de la Rosa FJ, Tyshevich A, Shavronskaya D, Alesse J, English N, Sheehan L, Syzrantsev N, Nesmelov A, Wendel HG, Strati P.   +10 more
europepmc   +1 more source